Dr Christian A. Stein, Chief Executive Officer
Before becoming chief executive officer of Ascenion in August 2001, Christian Stein headed the Patent and Licensing Agency of the German Human Genome Project (PLA) at the Fraunhofer Patent Centre for German Research for several years. In 2000 he also assumed responsibility for Bayern Patent, today called Bavarian Patent Alliance.
Christian Stein holds a PhD in molecular biology and obtained a Master of Science (MSc) in the Management of Intellectual Property Law in London. During this period he was also Assistant Editor-in-Chief for the international journal Antiviral Chemistry & Chemotherapy and was instrumental in founding Retroscreen Ltd, a thriving spin-off of the London Hospital Medical College. He founded and cofounded several companies in and outside the biotech field.
He is consultant and advisor for several EU programmes and regional and national expert groups, and serves on the boards of a number of biotechnology companies.
Christian Stein is Immediate Past President of the European Knowledge and Technology Transfer Professionals Association, ASTP-Proton, of which he has been a member since 2011. In addition, he serves on the Board of Directors at ATTP (Alliance of Technology Transfer Professionals), the international body for professionals engaged in technology transfer since 2011.
Thieß Gert Matzke, Senior Legal Counsel,
Authorized Signatory (Prokurist)
Thieß Gert Matzke has 14 years’ professional experience across the full spectrum of legal issues relevant to IP asset management, from structuring and negotiating complex licensing contracts, to research cooperation agreements and university spin-off financing deals.
Prior to joining Ascenion in 2002, he was a lawyer at Beiten Burkhardt Mittl & Wegener, focussing on intellectual property.
He has been licensed to practice as a lawyer in Germany since 1998. In addition, Thieß received a Master of Law in Intellectual Property from the Franklin Pierce Law Center, Concord NH, in 2002 and was admitted to the bar in New York in 2003.
Dr Stefanie Possekel, Director Technology Management
Stefanie Possekel spent more than 10 years in the pharmaceutical and biotech industry and has broad experience in in- and out licensing of clinical and preclinical projects. In particular, she successfully worked on a number of major research and development collaborations with academic institutions.
She joined Ascenion in October 2012 from Novartis, where she served as Director Strategic Alliances with global responsibilities for the Musculoskeletal Disease Area and Oncology. Prior to that she worked as Director Business Development at Santhera Pharmaceuticals, a Swiss-based specialty pharmaceutical company for orphan neuromuscular diseases.
Stefanie studied Biology at the Philipps University Marburg with a specific focus on Microbiology, Immunology, Genetics and Biochemistry and received her PhD in 1995. During her thesis she spent time at the Biocenter in Basel and worked closely with researchers at the Institute de Myologie in Paris, France. After her PhD, Stefanie spent 3 years in the Bay Area (California), working as a freelance science writer and scientific consultant to Affymetrix.
Dr Elisabeth von Weizsäcker,
Director Technology Management
Elisabeth von Weizsäcker is an experienced entrepreneur who also brings expertise from 16 years in management consultancy to Ascenion. She has accompanied numerous biotech start-ups during their founding and financing, and has advised public sector organizations in strategic, organizational and commercial matters.
Before joining Ascenion, she and a colleague founded the Metropolitan Consulting Group which grew to employ 15 staff. After 10 years they successfully sold the company to a strategic partner.
Elisabeth von Weizsäcker studied at the University of Freiburg and at the California Institute of Technology, subsequently gaining her PhD in molecular biology at the University of Cologne in the area of developmental biology. She then worked for the management consultancy Bossard Consultants, later moving to Gemini Consulting, from which the Metropolitan Consulting Group was spun out in 1998.